199 results about "Antitumor therapy" patented technology

The invention discloses an MOF-CQD enzyme-sensitive FRET hydrogel diagnosis and treatment probe as well as a preparation method and application thereof, and belongs to the technical field of biomedical detection and treatment. The probe takes a carboxyl carbon quantum dot (CQD) as a donor and a metal organic framework (MOF) as an acceptor, and the donor and the acceptor are connected through a replaceable enzyme response polypeptide bridge; when the fluorescence is complete, FRET is generated to quench the CQD fluorescence, the FRET is interrupted after the target enzyme cuts off the peptide bridge, and the blue / red fluorescence ratio is changed to realize nanomole-level quantitative detection and has self-correction capability. The probe is packaged in a four-arm PEG transparent hydrogel which does not need a photoinitiator and can be quickly self-crosslinked, and can be prepared into a film, a tooth socket and the like for POCT (point-of-care testing) of parts such as an oral cavity / skin and the like. After detection, the MOF is activated by illumination of 630-660 nm to generate active singlet oxygen, so that local antibacterial or anti-tumor treatment is realized, and a diagnosis and treatment integrated scheme is constructed.

The invention provides a whole-process targeting polypeptide, a drug compound thereof, a drug delivery system and application of the whole-process targeting polypeptide. The whole-process targeting polypeptide comprises pHA and VAP which are covalently connected through a bridging structure; the VAP is LVAP, a reverse sequence polypeptide of the LVAP, DVAP or SVAP; wherein the amino acid sequence of the LVAP is as shown in SEQ ID NO: 1; the SVAP is a D-configuration polypeptide of the LVAP; the DVAP is a D-configuration polypeptide of the LVAP inverted sequence polypeptide; the bridging structure is amino-monoethylene glycol-carboxylic acid or a derivative thereof. The whole-process targeting polypeptide not only can cross a blood-brain barrier, target tumor neovascularization, cross a blood-tumor barrier, target tumor mimicry vessels, tumor cells and stem cells thereof, but also has better tumor cell affinity, anti-tumor treatment and in-vivo safety effects. Meanwhile, the drug compound or the drug delivery system has a synergistic effect after being combined with a chemotherapeutic drug, and the anti-tumor drug effect can be remarkably improved.

The embodiment of the invention provides breast cancer targeting nanoparticles as well as a preparation method and application thereof. According to the embodiment of the invention, the breast cancer targeting nanoparticles are synthesized by preparing the pH sensitive polymer, carrying out co-coupling modification on the pH response polymer and the folic acid albumin nano-carrier and utilizing a controlled desolvation method; the breast cancer targeting nanoparticle is combined with a nano preparation passive targeting strategy, a tumor microenvironment stimulation response strategy and a folic acid active targeting strategy, the effects of an EPR effect, PEG shedding, charge overturning, folic acid ligand-receptor combination and the like are utilized, precise targeting and specific response of tumors are achieved, and targeted accumulation of drugs in a tumor microenvironment is comprehensively improved. Therefore, the breast cancer targeting nanoparticles prepared by the embodiment have the advantages of high targeting property, drug controlled release, improvement of solubility and absorptivity of indissolvable drugs and the like, so that the curative effect of the drugs can be enhanced, the toxic and side effects can be reduced, and the breast cancer targeting nanoparticles have wide application prospects in the field of anti-tumor treatment.

The invention relates to the technical field of biological medicine, in particular to immunogen cell death enhanced nano-vesicle hydrogel and application thereof. The invention provides a 3D-printable multifunctional synergistic immunogen cell death enhanced nano-vesicle hydrogel, which is characterized in that SerMA hydrogel is used as a matrix, cell membrane nano-vesicles (N (at) ILO) loaded with a photothermal agent IR1061, a chemotherapeutic drug OXA and a tumor acidic microenvironment regulator Lon are encapsulated, initial tumor immunogen cell death is triggered through a photothermal effect, and the tumor immunogen cell death enhanced nano-vesicle hydrogel can be used for 3D printing. OXA further enhances the ICD effect, Lon regulates the acidic tumor microenvironment to improve the T cell activity, and postoperative multi-mode synergistic anti-tumor treatment is achieved; meanwhile, the hydrogel also has excellent photocuring 3D printing capability, can be used for individually constructing a filling structure matched with a postoperative defect area, has a wide application prospect, and provides a new strategy and theoretical basis for postoperative comprehensive treatment of choroidal melanoma.

The invention belongs to the technical field of microorganisms, and particularly relates to application of parabacteroides dielsii SYSU-210 and metabolites thereof in cancer treatment. The parabacteroides dieldrii is a parabacteroides dieldrii SYSU-210 strain, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.32494, and the preservation date is November 04, 2024. According to the application disclosed by the invention, by carrying out anti-tumor treatment on tumor-bearing mice with colon cancer and breast cancer by using the single parabacteroides dieldrii SYSU-210 and a metabolite thereof, the screened SYSU-210 has a good treatment effect on both the colon cancer and the breast cancer, and effector T cell infiltration in tumors of the mice in a treatment group is remarkably increased; and when the compound is combined with an immunotherapy alpha PD-1 inhibitor or a chemotherapeutic drug oxaliplatin for use, the effect of synergistically enhancing the curative effect is shown.

The present invention belongs to the technical field of cancer immunotherapy, and particularly relates to a cholesterol-modified cationic liposome tumor vaccine, a preparation method therefor, and use thereof. In order to solve the problems of poor targeting and strong side effects of TLR agonists in anti-tumor treatment, the present invention provides a cationic liposome prepared from a cholesterol-modified 1V209 molecule, a cationic lipid component, cholesterol, and DSPE-PEG2000, and then the cationic liposome and ovalbumin 5 form the tumor vaccine by electrostatic adsorption. Animal experiments show that the vaccine can induce antigen-specific CD8+ T cells, activate lymphocytes, and generate stronger antigen cross-presentation, more memory T cells, antibodies, and cytokines. Prophylactic inoculation with the vaccine can significantly delay the progression of mouse melanoma and lymphoma and prolong the survival of mice. The combination use of the vaccine and a PD-1 checkpoint inhibitor can further enhance the anti-tumor effect. Therefore, the vaccine is a promising cancer vaccine.

The invention discloses a preparation method of an RNA targeted photosensitizer and an application of the RNA targeted photosensitizer in anti-tumor treatment, and belongs to the technical field of fine chemical engineering. The photosensitizer is modified on the basis of a fluorescent molecule parent, and the RNA targeted photosensitizer is constructed. The photosensitizer disclosed by the invention can be self-assembled into nanoparticles in an aqueous solution, shows good RNA targeting, effectively generates reactive oxygen species through I-type and II-type mechanisms, and shows excellent performance in the aspects of long-term fluorescence imaging in tumor cells and anti-tumor treatment in normal-oxygen and hypoxic environments; the fluorescence of the photosensitizer Se-cy is enhanced by about 230 times after RNA is added, and the fluorescence duration can be kept as long as 40 hours in in-vitro cells; and the fluorescent label can be kept for 4 days in vivo, shows excellent fluorescent durability, and has a remarkable anti-tumor effect on tumor-bearing mice.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a dammarane sapogenin-isatin derivative and application thereof in anti-tumor treatment. The dammarane sapogenin-isatin conjugate is constructed by taking dammarane sapogenin as a mother nucleus, deriving the dammarane sapogenin and chloroacetic acid and then introducing an indolone structural unit, and R1, R2 and R3 are as described in the claims and the specification. According to the invention, isatin fragments and ginsenoside are coupled for the first time, the anti-tumor activity of the compounds is systematically evaluated, and the action mechanism research of the compounds in colorectal cancer and other tumors is further developed. Results show that the obtained compound has relatively good anti-tumor efficacy, tumor cell selectivity, relatively low toxicity and relatively high bioavailability, and shows good patent medicine potential and wide market prospects.

The invention relates to the technical field of traditional Chinese medicine processing, and discloses traditional Chinese medicine processing equipment for traditional Chinese medicine anti-tumor treatment, which comprises a crushing box, the front surface of the crushing box is fixedly connected with a first motor, the output end of the first motor is provided with crushing rollers through a coupler, and the two crushing rollers are meshed with each other through a gear set; a screen is arranged in the smashing box, a suction opening of the smashing box synchronously moves along with the carding component through a suction fan and a conveying pipe, large particles which cannot pass through the screen on the screen face can be accurately and efficiently sucked up in time, and the large particles are conveyed to the top of the smashing box again through the conveying pipe and fall into the position between the two smashing rollers to be smashed again forcibly. The trouble that traditional equipment needs to be shut down to manually return materials is avoided, the materials are smashed multiple times in the single machining process, the smashing efficiency is remarkably improved, the carding plate horizontally reciprocates above the screen, large-particle materials are continuously carded, cut and smashed, and screen holes are effectively prevented from being blocked.

The invention belongs to the technical field of biomedical materials, and discloses pH-responsive injectable hydrogel as well as a preparation method and application thereof. Comprising the following steps: (1) dissolving sodium alginate in water to form a uniform solution; (2) adding a fat-soluble small molecule drug and Fe3O4 nanoparticles into the solution, carrying out high-speed shearing dispersion under an ice-water bath condition to form a drug / nano composite system, and standing; and (3) sequentially adding a calcium carbonate suspension and glucolactone into the drug / nano composite system, uniformly stirring, and incubating until the mixture is completely cured to obtain the pH-responsive injectable hydrogel. The hydrogel obtained by the invention not only has excellent injectability and pH response release performance, but also can remarkably improve the loading efficiency of fat-soluble drugs, and provides a new technical approach for realizing local anti-tumor treatment.

The invention discloses a fluorescent / photoacoustic dual-mode diagnosis and treatment probe for detection and photodynamic removal of senescent cells, a preparation method and application, the probe takes a sulfur-substituted hemicyanine dye as a parent structure, a novel bromo-glycoside ligand is covalently coupled, and a blue-green solid is obtained after gradient purification. The probe system shows a remarkable optical response characteristic on beta-galactosidase (beta-Gal) and ideal singlet oxygen (1O2) generation efficiency; an optical signal and a photodynamic therapy effect of the probe can be specifically activated by beta-galactosidase (beta-Gal) overexpressed in cancerous cells and senescent cells under a light excitation condition; the result is successfully verified in a palbociclib-induced senescence melanoma model. According to the probe disclosed by the invention, collaborative regulation and control of dual-mode visual monitoring and precise photodynamic therapy of beta-Gal enzyme activity are realized for the first time, a novel tool is provided for researching a molecular mechanism of cell aging and developing a diagnosis and treatment strategy of aging-related diseases, and the probe has a remarkable application value in the fields of anti-tumor treatment and degenerative diseases.

The invention belongs to the technical field of photosensitizer preparation and biological medicine, and particularly relates to a photosensitizer and a preparation method and application thereof. The I-type photosensitizer Nile violet NV is designed and synthesized on the basis of fluorescent dye Nile red through monatomic substitution and structural modification, and the structural formula of the I-type photosensitizer Nile violet NV is shown in the formula I. The photosensitizer based on Nile red can generate O2 <.-> after illumination, and has I-type photodynamic therapy potential; the nanomaterial has a good active oxygen generation capability in tumor cells, and is beneficial to the application of tumor photodynamic therapy. The invention proves that the compound shows an excellent anti-tumor effect in mouse solid tumors and can be widely applied to the field of anti-tumor treatment; meanwhile, the I-type photosensitizer is simple in synthesis method, good in biological safety and remarkable in tumor photodynamic therapy effect, so that the I-type photosensitizer has good practical application value.

The invention belongs to the technical field of nano materials and anti-tumor treatment medicines, and discloses cordyceps sinensis mycelium polysaccharide-copper selenide with dual effects of inducing tumor cell apoptosis and copper death as well as a preparation method and application thereof. The preparation method of the cordyceps sinensis mycelium polysaccharide-copper selenide comprises the following steps: taking cordyceps sinensis mycelium polysaccharide as a template, adopting a soft template method, reducing Na2SeO3 through Vc, and adding CuSO4 to prepare the cordyceps sinensis mycelium polysaccharide-copper selenide. The cordyceps sinensis mycelium polysaccharide-copper selenide can selectively kill tumor cells and induce apoptosis and copper death of the tumor cells at the same time, and has huge application potential in the aspect of tumor prevention and treatment.

This application discloses a purino[1,2-a]carbazolin derivative, its preparation method, and its application. Specifically, it discloses a compound having the structure shown in Formula I, or its stereoisomers, solvates, metabolites, pharmaceutically acceptable salts, cocrystals, or prodrugs: ; wherein R1 and R2 are each independently selected from hydrogen, hydroxyl, carboxyl, substituted or unsubstituted C1-C6 alkyl, -CONH-R3, and -COO-R4; wherein R3 is a substituted or unsubstituted C1-C5 alkyl, and the substituent can be any of cyano, halogen, alkylC1-C5 alkoxy, C1-C5 alkylsulfonyl, di(C1-C5 alkyl)amino, nitrogen-containing heterocyclic, aryl, and C1-C5 heteroaryl; R4 is selected from any of substituted or unsubstituted aryl C1-C5 alkyl and nitrogen-containing saturated heterocyclic C1-C5 alkyl. This compound can be used as a TDP1 inhibitor for antitumor therapy.

The present invention provides a long-acting dual-target chimeric antigen receptor, nucleic acid molecule, recombinant vector, cell, and application thereof. The dual-target chimeric antigen receptor comprises two independent transmembrane protein chains, wherein the first CAR chain targets a scFv of the first target, and the intracellular signal comprises a second signal and an intracellular transduction signal or only an intracellular transduction signal; the second CAR chain targets a scFv of the second target, and the intracellular signal comprises a costimulatory signal and a JAK enzyme activation transduction domain. The CAR-T cells prepared by the present invention have a strong and persistent killing effect on tumor cells that simultaneously express the first and second targets, and can be used for the anti-tumor treatment of solid tumors.

This invention belongs to the pharmaceutical field, specifically relating to an anti-tumor angiogenesis drug potentiator, an anti-tumor drug composition, and its application. Firstly, this invention discovers that SHCBP1 inhibitors can enhance the therapeutic effect of anti-tumor angiogenesis drugs and can be used as potentiators for anti-tumor angiogenesis drugs. Secondly, when SHCBP1 inhibitors are used in combination with anti-tumor angiogenesis drugs, or in combination with anti-tumor angiogenesis drugs and PD-1 inhibitors, tumor angiogenesis can be normalized and its window period prolonged, significantly improving the efficacy of immunotherapy, anti-angiogenesis, and anti-tumor therapy, showing broad application prospects.

The application discloses a kind of Man-PFH-ICG@PLGA nanoparticles and preparation method and application thereof, belong to composite material preparation technical field.The application uses PLGA as carrier, using polylactic acid-glycolic acid (PLGA) nanoparticles (NPs) to mark the surface of it with mannose, and ICG and oxygen-carrying PFH are embedded therein, the obtained Man-PFH-ICG@PLGA nanoparticles have excellent targeting effect on the overexpression of mannose receptor on the surface of tumor cells, significantly promote the effective endocytosis of cells in vitro and tumor enrichment in vivo, directly relieve the hypoxic environment of tumor;It can also supplement oxygen by endogenous, to activate the TRPA1 channel overexpressed on the surface of tumor cells by ROS generated by cells, so as to inhibit cell respiration, reduce oxygen consumption, indirectly relieve the hypoxic environment of tumor, effectively inhibit the growth of tumor cells, and provide a new idea for clinical exploration of antitumor therapy.

Provided are a polypeptide-conjugated drug, a method for preparing same, and use thereof. Specifically, the present invention relates to a polypeptide-conjugated drug as represented by general formula (I) and use thereof, wherein P comprises a polypeptide of formula (II), L is selected from a non-cleavable linker or a cleavable linker, and Drug is an antitumor agent. The polypeptide-conjugated drug can specifically bind to GRPr with high affinity and thereby efficiently kill tumor cells, thus providing a targeted antitumor therapy for the field of tumor treatment. P-L-Drug (I) Ser-Tyr-Gln-X1-Ala-X2-βAla-X3-X4-Nle (II)

This invention provides a chlorambucil NO donor prodrug having the structure shown in Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I). It involves reacting chlorambucil with a dihaloalkane to obtain a halochlorambucil intermediate; reacting the halochlorambucil intermediate with silver nitrate to obtain the chlorambucil NO donor prodrug. This invention applies the chlorambucil NO donor prodrug to the preparation of drugs for treating tumors, such as melanoma, lymphoma, leukemia, or breast cancer. This nanosystem exhibits good NO release levels under light irradiation. Cellular experiments have demonstrated its good antitumor effect, providing a new strategy for multimodal combined antitumor therapy.

The invention provides maslinic acid PROTACs as well as a preparation method and application thereof, and belongs to the technical field of drug development. According to the invention, maslinic acid is taken as a POI ligand, lenalidomide and fluoro-thalidomide are taken as E3 ligands, and linker selects a PEG chain or an aliphatic chain, so that the anti-cancer activity of the compound is superior to that of maslinic acid, and the compound has a good potential application prospect in the aspect of anti-tumor treatment.

The invention belongs to the technical field of biological medicine, and discloses a medicine for in-vivo engineering CAR-T and a preparation method thereof. The drug provided by the invention comprises a first RNA and a second RNA which are used for coding a chimeric antigen receptor in a specific molar ratio, the second RNA is used for coding at least two cytokines of CCL19, IL-17, IL-15, IL-2 or IL-24, by adopting the drug, the gene delivery efficiency and targeting of in-vivo engineered CAR-T can be improved, better T cell transformation and CAR + T cell generation effects are realized, the CAR-T cell depletion is reduced, and the drug has a good application prospect. According to the present invention, the CAR-T gene is constructed, such that the CAR-T gene can survive for a long time in the tumor microenvironment and continuously provide the treatment effect, has the excellent anti-tumor treatment effect, has the excellent application prospect in the in-vivo engineering CAR-T treatment, and has the important significance on the promotion of the efficient, safe and economical development of the CAR-T treatment.

The present invention relates to the field of biomedicine, and in particular to immunogenic cell death-enhancing nanovesicle hydrogels and their applications. The present invention provides a 3D-printable, multifunctional, synergistic immunogenic cell death-enhancing nanovesicle hydrogel. The hydrogel uses SerMA hydrogel as a matrix and encapsulates cell membrane nanovesicles (N@ILO) loaded with the photothermal agent IR1061, the chemotherapy drug OXA, and the tumor acidic microenvironment regulator Lon. The hydrogel triggers initial tumor immunogenic cell death through the photothermal effect, further enhances the ICD effect through OXA, and modulates the acidic tumor microenvironment through Lon to increase T cell activity, achieving multimodal synergistic anti-tumor therapy after surgery. The hydrogel also possesses excellent photocurable 3D printing capabilities and can be used to construct personalized filling structures that match postoperative defect areas. The hydrogel has broad application prospects and provides a new strategy and theoretical basis for the comprehensive postoperative treatment of choroidal melanoma.

Tumor-selective expression of therapeutic molecules by bacteria is achieved by one or more AND, NOR, OR, NOT and / or NAND gate genetic circuits. The therapeutic molecules can be proteins, metabolites or catabolites, and may also be immunotherapeutics or immunotherapeutic cytotoxins. Single or multiple expression components may be used. Tumor selective expression of multimeric proteins utilizes multimerization as to complete the genetic circuit. Genetic circuits that are unlinked, function to achieve a combined effect on specificity of delivery of antitumor therapeutic molecules. Compositions and methods to generate silica, PEG and Poly-HPMA coated bacteria are also provided. Compositions and methods for selectively sensing or imaging tumors are also described.

The invention provides a pAKT-targeted small molecule compound, a PET molecular probe precursor, a PET molecular probe and a preparation method and application of the PET molecular probe. The PET molecular probe disclosed by the invention is a radioactive probe which is modified on the basis of a chemical structure of a medicine Caprivastib (AZD5363) and is marked by 68Ga and is targeted to pAKT. According to the probe, structural modification is carried out on Capivasertib, the area, combined with PKA, of Capivasertib is changed, precursor molecules combined with pAKT in a high-specificity mode are obtained, and the precursor molecules are further researched, developed and modified into the radioactive probe targeting pAKT capable of being used for PET imaging. The probe has relatively low abdominal nonspecific uptake, can effectively distinguish tumors with high expression and low expression of pAKT in vivo, and can predict and early evaluate the response condition of the tumors to a PI3K / AKT pathway related inhibitor. Therefore, the probe has a very strong clinical application prospect, on one hand, the probe can be used for analyzing the expression quantity of pAKT in tumor tissues; on the other hand, the probe can also be used for predicting and early evaluating the effect of the PI3K / AKT pathway related inhibitor in anti-tumor treatment.

The present invention relates to an EZH1 / 2 inhibitor, a preparation thereof, and a use thereof in anti-tumor therapy, specifically comprising a compound represented by formula I or formula II, or a deuterated compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and further comprising a pharmaceutical composition of the compound, and a use of the foregoing as an EZH1 / 2 inhibitor in the preparation of medication for treating related diseases.

This invention provides a chimeric antigen receptor comprising an NFIX-encoding gene, a self-cleaving peptide sequence F2A, and a CAR-encoding sequence. The NFIX-encoding gene is located upstream and is linked to the CAR-encoding sequence via the self-cleaving peptide sequence F2A. The sequence of the NFIX-encoding gene is shown in SEQ ID NO. 01, and the sequence of the self-cleaving peptide sequence F2A is shown in SEQ ID NO. 03. This invention also provides a chimeric antigen receptor T cell expressing the aforementioned chimeric antigen receptor. This invention further provides the application of the aforementioned chimeric antigen receptor or the aforementioned chimeric antigen receptor T cell in the preparation of drugs for treating cancer. This invention improves the antitumor therapeutic effect of CAR-T cells by introducing the NFIX expression element into engineered T cells, thereby enhancing their functional stability, proliferative capacity, and cytotoxic activity under continuous antigen stimulation.

The application discloses a 2,2'-biquinoline-4,4'-dicarboxylic aliphatic amino acid derivative, and a preparation and application thereof, and belongs to the technical field of medicines.The structure of the 2,2'-biquinoline-4,4'-dicarboxylic aliphatic amino acid derivative is shown in the following formula: wherein RNH is selected from the group consisting of structures that are stable, have low toxicity, have antitumor activity, and can be used as effective components of antitumor drugs for antitumor treatment.The preparation process of the 2,2'-biquinoline-4,4'-dicarboxylic aliphatic amino acid derivative is simple, and the 2,2'-biquinoline-4,4'-dicarboxylic aliphatic amino acid derivative is easy to be industrialized when being used for preparing antitumor drugs.

The invention belongs to the cross technical field of cell engineering, nano-drugs and biological manufacturing, and particularly discloses a drug-loaded vesicle based on denucleated cells as well as a preparation method and application of the drug-loaded vesicle. According to the invention, a cell suspension and a cytoskeleton relaxant are co-incubated to relax an actin skeleton and weaken nucleoplasm connection; then loading the treated cell suspension on a multi-layer discontinuous density gradient centrifugal medium, realizing physical separation of cell nucleuses and cytoplasm through high-speed centrifugation according to buoyancy density difference, and collecting components of a specific interface to obtain high-purity denucleated cells with a complete membrane structure; then co-incubating the denucleated cells and ROS response type lipidosome (co-carrying therapeutic siRNA and a sound-sensitive agent Ce6) prepared in advance, so that the lipidosome is wrapped or anchored by a denucleated cell membrane; finally, the composite system is subjected to extrusion treatment through a microporous membrane, the drug-loaded vesicles uniform in particle size and stable in structure are obtained, and the drug-loaded vesicles are suitable for various application scenes such as anti-tumor treatment and RNA vaccine delivery.

The invention provides a paclitaxel precursor nano-drug as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. Comprising a paclitaxel dimer prodrug and 7-ethyl10-hydroxy-camptothecin loaded on the paclitaxel dimer prodrug. According to the invention, a paclitaxel dimer prodrug is used as a self-assembly monomer to construct a PTX-SN38 synergistic treatment nano system, and the system has the advantages of dispersibility in water, biocompatibility, tumor specific response, synergistic treatment and the like, and can effectively solve the limitation of paclitaxel and SN38 in anti-tumor treatment.

This invention discloses a class of non-conjugated N-methyl site-linked photosensitive dyes, their preparation methods, and applications, relating to the field of fine chemical organic dye technology. The photosensitive dyes have the structure of general formula 1. These non-conjugated N-methyl site-linked photosensitive dyes possess no heavy atom modification, dual-cation characteristics, and exhibit near-infrared absorption and emission, high molar extinction coefficient, and high photosensitization efficiency, specifically generating type I and type II reactive oxygen species. They demonstrate excellent tumor cell killing ability under near-infrared light irradiation, showing promising application prospects in anti-tumor therapy.